All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Trastuzumab Deruxtecan May Represent Potential Option for HER2-Expressing Solid Tumors

August 28th 2023

Funda Meric-Bernstam, MD, discusses the design of the DESTINY-PanTumor02 trial, details the antitumor activity and safety of T-DXd in HER2-expressing solid tumors, and shares additional analyses that will be coming down the pike.

Bazhenova Details Potential Pathways Forward for Targeting KRAS Mutations in NSCLC

August 28th 2023

Lyudmila A. Bazhenova, MD, discusses upcoming inhibitors of interest in the combination therapy space for patients with KRAS G12C–mutant NSCLC.

Petrylak Provides Perspective on the Nationwide Cisplatin/Carboplatin Shortage

August 28th 2023

Daniel P. Petrylak, MD, discusses strategies he and his colleagues at Yale Cancer Center have employed to reduce the effect of the current chemotherapy shortage on patients, and emphasizes the need to reassess current manufacturing strategies in an effort to potentially mitigate future drug shortages.

Radical Cystectomy or Bladder Preservation: Understanding Optimal Therapy for Locally Advanced Bladder Cancer

August 28th 2023

Neil Desai, MD, MHS, expands on the need for further research regarding potential treatment strategies for patients with locally advanced, nonmetastatic muscle-invasive bladder cancer who may not benefit from standard approaches.

Estrogen Receptor Mutation Study Suggests Potential Treatments For Endometrial Cancers

August 28th 2023

Researchers at Huntsman Cancer Institute identified potential new treatment options for people with endometrial cancer.

TTFields Plus Paclitaxel Misses OS End Point in Platinum-Resistant Ovarian Cancer

August 28th 2023

The addition of tumor treating fields to paclitaxel did not result in a statistically significant improvement in overall survival vs paclitaxel alone in patients with platinum-resistant ovarian cancer, failing to meet the primary end point of the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial.

Komrokji Examines Differences Between the WHO and ICC MDS Criteria

August 28th 2023

Rami Komrokji, MD, discusses an international dataset analysis of the 2 current classification systems for patients with myelodysplastic syndromes, as well as the next steps being taken to develop a more harmonized classification system.

Subcutaneous Trastuzumab Proves Safe and Tolerable in HER2+ Metastatic Breast Cancer

August 28th 2023

The safety profile of subcutaneous trastuzumab was consistent with the known profile of intravenous administration of the agent and there were no new concerns related to prolonged exposure in patients with HER2-positive metastatic breast cancer.

Niraparib Maintenance Extends PFS in Newly Diagnosed Ovarian Cancer

August 27th 2023

Maintenance therapy with the PARP inhibitor niraparib prolonged progression-free survival vs placebo in patients with newly diagnosed advanced ovarian cancer.

Postoperative ctDNA Provides Prognostic Value for DFS Outcomes in CRC

August 26th 2023

Circulating tumor DNA status at the time of postoperative minimal residual disease assessment was found to be a prognostic factor for disease-free survival in patients with radically resected stage II to IV colorectal cancer.

European Medicines Agency Grants Orphan Drug Designation to Mitazalimab for Pancreatic Cancer

August 25th 2023

The European Medicines Agency has granted orphan drug designation to mitazalimab for use in patients with pancreatic cancer.

Rural Patient Populations at Higher Risk of Lung Cancer Mortality

August 25th 2023

Logan Roof, MD, discusses the importance of investigating demographic disparities that exist in lung cancer mortality, expands on the results of the population-based CDC database analysis, and discusses potential next steps to address these disparities in the future.

FDA Grants Fast Track Status to ALE.C04 for Recurrent or Metastatic CLDN1+ HNSCC

August 25th 2023

The FDA has granted fast track designation to ALE.C04 for use as a potential therapeutic option in patients with recurrent or metastatic, Claudin-1–positive head and neck squamous cell carcinomas.

VEGF and HIF Pathway Inhibition Point Toward an Increasingly Tolerable RCC Armamentarium

August 25th 2023

Qian (Janie) Qin, MD, discusses the current RCC treatment landscape, ongoing research with belzutifan combination therapies, and considerations for investigating CAR T-cell therapy in patients with solid tumors.

Fox Chase Researcher Receives Grant for Study of RNA, Telomerase and Implications for Disease

August 25th 2023

A Fox Chase Cancer Center researcher has been awarded a $2.5 million grant from the National Institute of General Medical Sciences to investigate RNA structure and stability, work that has implications for cancer, Alzheimer’s, and other degenerative diseases and continues the Fox Chase legacy of basic research.

FDA Approval Sought for Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

August 25th 2023

A supplemental biologics license application seeking the expanded approval of amivantamab-vmjw in combination with carboplatin plus pemetrexed for use in the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations has been submitted to the FDA.

LEAP-010 Trial Discontinued After OS Projection With Pembrolizumab/Lenvatinib in Metastatic HNSCC

August 25th 2023

The combination of pembrolizumab and lenvatinib demonstrated a statistically significant improvement in progression-free survival and objective response rate but failed to improve overall survival compared with pembrolizumab plus placebo as frontline therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Dara-KRd Quadruplet Makes Waves in Newly Diagnosed Multiple Myeloma

August 25th 2023

Luciano J. Costa, MD, PhD, discussed extended follow-up data from the trial and explained how the results may affect frontline treatment decisions in multiple myeloma.

Case Studies Illustrate the Importance of Nuanced Treatment Discussions in Advanced RCC

August 25th 2023

Hans Hammers, MD, PhD, outlines 3 cases of patients with renal cell carcinoma, detailing how each patient’s disease presented and how clinicians proceeded with treatment.

Cabozantinib Efficacy Prompts CABINET Trial Unblinding in Advanced Pancreatic and Extra-Pancreatic NETs

August 24th 2023

Interim data from the phase 3 CABINET trial demonstrated significant improvement in progression-free survival with cabozantinib vs placebo in patients with advanced pancreatic or extra-pancreatic neuroendocrine tumors following progression on prior systemic therapy.